Transcript

Jenna is driving a profound transformation in pharmaceutical industries. According to Deloitte, top biopharma companies could capitalize on AI investment and drive revenue uplift and cost reduction up to 30 to 40% primarily from R&D, about 15 to 25% from manufacturing and supply chain, and 25 to 35% in commercial areas. Pharmaceutical and life science professionals are leveraging AI for drug discovery, where it plays a pivotal role in streamlining patient recruitment, monitoring trial progress, and identifying risk areas, leading up to 70% cost savings per trial and 80% timeline reduction. Generative AI is at the heart of all this revolution extended its influence across the entire life cycle, from Doug discovery to clinical trials, regulatory submission, and even personalized marketing. As per a index report, 202571 percent of companies now use Genai in at least one business function, including clinical documentation, design, simulation, and intelligent search. In medtech, the economic impact is equally compelling. McKenzie estimates that Gen. AI could unlock 60 billion to 110 billion annually by driving up productivity and accelerating growth in drug development and commercialization. Furthermore, it can also enhance every aspects of pharmaceutical operation value chain including sourcing, manufacturing, quality control and supply chain with potential opportunity of 4 to 7 billion. Jenny is no longer a futuristic concept, it's a present day catalyst that reshaping how drugs are discovered, developed and delivered. As its capabilities continues to evolve, we can expect faster, more cost effective and highly targeted treatments, making end to end AI driven drug development a near term reality.